Human papillomavirus (HPV) infection drives tumorigenesis in the majority of cervical,
oropharyngeal, anal, and vulvar cancers. Genetic and epidemiologic evidence has …

Herein, we review the epitope approach to vaccine development, and discuss how
knowledge of HLA supertypes might be used as a tool in the development of such vaccines …

The mechanism of tumor-associated T cell dysfunction remains an unresolved problem of
tumor immunology. Development of T cell defects in tumor-bearing hosts are often …

Tumor-induced immunosuppression is one of the crucial mechanisms of tumor evasion of
immune surveillance. It contributes greatly to the failure of cancer vaccines. Immature …

The tumor-associated-Ag MART-1 is expressed by most human melanomas. The genes
encoding an αβ TCR from a MART-1-specific, HLA-A2-restricted, human T cell clone have …

The potential to harness the potency and specificity of the immune system underlies the
growing interest in cancer immunotherapy. One such approach uses bone marrow–derived …

The outcome of antigen recognition by naive CD8+ cytotoxic T lymphocytes (CTLs) in the
periphery is orchestrated by CD4+ T-helper cells, and can either lead to priming or …

Acquisition of human papillomavirus (HPV) results in an infection of variable duration which
may or may not be associated with clinically apparent lesions. Lesions caused by skintropic …

Therapeutic vaccination trials, in which patients with cancer were vaccinated with minimal
CTL peptide in oil-in-water formulations, have met with limited success. Many of these …

Vaccination with synthetic peptides representing cytotoxic T lymphocyte (CTL) epitopes can
lead to a protective CTL-mediated immunity against tumors or viruses. We now report that …